\nThermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, hosted its Investor Day today. Chairman and Chief Executive Officer Marc N. Casper and members of the senior leadership team highlighted the company\u2019s industry leadership and the essential role of its best-in-class products and services to customers around the world.<\/p>\n
\n“Our customers value Thermo Fisher as their trusted partner,\u201d said Marc N. Casper, chairman and chief executive officer, Thermo Fisher Scientific. \u201cOur unique scale and depth of capabilities advance scientific discovery and position us incredibly well in an increasingly AI-enabled world.\u201d<\/p>\n
\nCasper continued, \u201cWe have a track record of delivering share gain through our proven growth strategy, operational excellence through our PPI Business System and creating value through disciplined capital deployment. We are incredibly well positioned in attractive and improving end markets to create value for our stakeholders and build a very bright future for our company. We are actively managing the company to deliver outstanding financial performance in the short- and long-term.\u201d<\/p>\n
\nAt today\u2019s event, Thermo Fisher Scientific highlighted:<\/p>\n
- \n
- Attractive end markets that are fueled by enduring long-term trends<\/b>\n
- \n
- \nThermo Fisher serves an attractive $255 billion market with improving demand trends and strong long-term growth fundamentals.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n
- Incredibly well-positioned industry leadership<\/b>\n
- \n
- \nOur industry-leading businesses enable our customers\u2019 success and benefit from the scale and depth of our combined capabilities.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n
- Proven growth strategy drives share gain<\/b>\n
- \n
- \nInnovation: Our cutting-edge technologies accelerate our customers\u2019 innovation and enhance their productivity.<\/p>\n<\/li>\n
- \nTrusted Partner: Our expertise, scale, and depth of capabilities make us the partner of choice to solve customers\u2019 most important challenges.<\/p>\n<\/li>\n
- \nCommercial engine: Our exceptional reach and depth of engagement create a competitive advantage.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n
- Practical Process Improvement Business System (PPI) enables outstanding execution<\/b>\n
- \n
- \nPPI is the core of Thermo Fisher\u2019s culture, with a focus on continuous improvement that drives quality, productivity and customer allegiance and engages every colleague to find a better way, every day.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n
- AI is a powerful accelerator for the company\u2019s future<\/b>\n
- \n
- \nAI will accelerate scientific breakthroughs and improve productivity and returns on drug discovery \u2013 fueling additional investment into our customers\u2019 drug pipelines and driving additional demand for our capabilities.<\/p>\n<\/li>\n
- \nWe are uniquely positioned to capture AI-driven growth through our presence across the full drug development value chain.<\/p>\n<\/li>\n
- \nAI and automation are accelerating the impact of PPI across the company as we deploy the capabilities at scale.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n
- Disciplined approach to capital deployment creates tremendous value<\/b>\n
- \n
- \nA disciplined combination of strategic M&A and returning capital to shareholders enables us to further strengthen the company\u2019s industry leadership and creates significant value for our shareholders.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n
- Outstanding track record of financial performance and an exceptional long-term outlook<\/b>\n
- \n
- \nThermo Fisher\u2019s proven growth strategy and disciplined approach to capital deployment position the company to deliver 7% organic revenue CAGR and low-teens adjusted EPS growth over the long term.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n
Webcast Replay<\/b><\/p>\n
\nTo access the presentation materials from today\u2019s investor event, visit the Company\u2019s investor relations website<\/a>.<\/p>\n
About Thermo Fisher Scientific<\/b><\/p>\n
\nThermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $45 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Gibco, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com<\/a>.<\/p>\n
Forward-Looking Statements<\/b><\/p>\n
\nThis press release contains \u201cforward-looking statements\u201d within the meaning of applicable securities laws, including those relating to the growth of our end markets, our growth strategy and our business generally. Each of the forward-looking statements we make in this press release involves risks and uncertainties, many of which relate to matters beyond our control and could cause actual results to differ materially from these forward-looking statements. A discussion of such factors and other risks that affect our business is contained in our most recent reports on Form 10-K and Form 10-Q under the heading \u201cRisk Factors.\u201d These filings are on file with the SEC and available in the \u201cInvestors\u201d section of our website under the heading \u201cSEC Filings.\u201d These forward-looking statements are based on our current expectations and speak only as of the date of this press release. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, in the event of new information, future developments or otherwise.<\/p>\n
Use of Non-GAAP Financial Measures<\/b><\/p>\n
\nIn addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), Thermo Fisher uses certain non-GAAP financial measures, including adjusted earnings per share which excludes certain transaction-related costs, including charges for the sale of inventories revalued at the date of acquisition and significant transaction-related third-party costs; restructuring and other costs\/income; amortization of acquisition-related intangible assets; certain other gains and losses that are either isolated or cannot be expected to occur again with any regularity or predictability, tax provisions\/benefits related to the previous items, benefits from tax credit carryforwards, the impact of significant tax audits or events, equity in earnings of unconsolidated entities and the results of discontinued operations, as applicable. Thermo Fisher excludes the above items because they are outside of the company’s normal operations and\/or, in certain cases, are difficult to forecast accurately for future periods. We also use organic revenue growth, which is reported revenue growth, excluding the impacts of acquisitions\/divestitures and the effects of currency translation. Thermo Fisher reports this measure because its management believes that in order to understand the company\u2019s short-term and long-term financial trends, investors may wish to consider the impact of acquisitions\/divestitures and\/or foreign currency translation on revenues. Thermo Fisher management uses this measure to forecast and evaluate the operational performance of the company as well as to compare revenues of current periods to prior periods. Thermo Fisher believes that the use of non-GAAP measures helps investors to gain a better understanding of the company’s core operating results and future prospects, consistent with how management measures and forecasts the company’s performance, especially when comparing such results to previous periods or forecasts. Thermo Fisher does not provide GAAP financial measures on a forward-looking basis because we are unable to predict with reasonable certainty and without unreasonable effort items such as the timing and amount of future restructuring actions and acquisition-related charges as well as gains or losses from sales of real estate and businesses, the early retirement of debt and the outcome of legal proceedings. The timing and amount of these items are uncertain and could be material to Thermo Fisher\u2019s results computed in accordance with GAAP.<\/p>\n
<\/p>\n
View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260520211163\/en\/<\/a><\/span><\/p>\n
\nMedia Contact Information:
\n
Sandy Pound
\n
Phone: 781-622-1223
\n
E-mail: sandy.pound@thermofisher.com
\n<\/a>
Website: www.thermofisher.com<\/a><\/p>\n\nInvestor Contact Information:
\n
Rafael Tejada
\n
Phone: 781-622-1356
\n
E-mail: rafael.tejada@thermofisher.com<\/a><\/p>\n\n\u00a0<\/p>\n
KEYWORDS:<\/b> Massachusetts United States North America<\/p>\n
INDUSTRY KEYWORDS:<\/b> Biotechnology Technology Other Health Health General Health Pharmaceutical Other Science Other Technology Research Artificial Intelligence Science<\/p>\n
- \nThermo Fisher\u2019s proven growth strategy and disciplined approach to capital deployment position the company to deliver 7% organic revenue CAGR and low-teens adjusted EPS growth over the long term.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20260520211163\/en\/1387941\/3\/Thermo_Fisher_Scientific.jpg\")
<\/td>\n<\/tr>\n